Study of SHR-1826 for advanced lung cancer
Part of Cancer clinical trials.
This trial tests an investigational drug called SHR-1826 for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer that has been confirmed by a biopsy.
- You are in fairly good physical health (able to do light activities and care for yourself).
- You have at least one tumor that can be measured on imaging scans.
- You can provide a tumor sample from a previous biopsy or a new biopsy.
- Your cancer has not spread to the brain or spinal cord lining, or if it has, it is well controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs—SHR-A1921 and adebrelimab—for people with advanced non-small cell lung cancer (NSCLC) whose cancer has grown after standard first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This study tests two new drugs (SHR-A1921 and SHR-A2009) for people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after previous treatments, including antibody-drug conjugate therapy. The goal is to see if these drugs can help control the cancer.
This trial tests an investigational drug called SHR-A1811 in people with non-small cell lung cancer that has spread or cannot be removed by surgery and has a HER2 alteration. The goal is to see if the drug is effective and safe for this type of cancer.
This trial tests a new targeted drug (SHR-A1811) combined with an immunotherapy drug (adebelimumab) before surgery for patients with early-stage, resectable lung cancer that has a specific HER2 alteration. The goal is to shrink the tumor and improve outcomes.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.